Free public records show Alembic Therapeutics in 30 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
221 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
13 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
9 recalls since 2015 (9 for medicines)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Markets we cover where free public records show Alembic Therapeutics: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Alembic Therapeutics is in.
Stories on the topics Alembic Therapeutics works in.
170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and…
Read
Depression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress…
Read
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read